Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 15/20 | 0.61 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.52 |
| ▸ | RAF1 | P04049 | 1/20 | 0.47 |
| ▸ | TYK2 | P29597 | 2/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22208956 | 1.00 | SCN10A (0.61) | SCN10AGRM4RAF1TYK2JAK2 | |
| SCHEMBL20639170 | 0.89 | SCN10A (0.56) | SCN10AGRM4RAF1 | |
| SCHEMBL22208657 | 0.88 | SCN10A (0.62) | SCN10AGRM4RAF1 | |
| SCHEMBL31697125 | 0.88 | SCN10A (0.62) | SCN10AGRM4RAF1 | |
| SCHEMBL22208848 | 0.87 | SCN10A (0.61) | SCN10AGRM4RAF1 | |
| SCHEMBL31697196 | 0.87 | SCN10A (0.61) | SCN10AGRM4RAF1 | |
| SCHEMBL31697271 | 0.84 | SCN10A (0.52) | SCN10AGRM4TYK2JAK2 | |
| SCHEMBL22208836 | 0.84 | SCN10A (0.52) | SCN10AGRM4TYK2JAK2 | |
| SCHEMBL25086673 | 0.83 | SCN10A (0.71) | SCN10AGRM4RAF1 | |
| SCHEMBL22219565 | 0.82 | SCN10A (0.61) | SCN10AGRM4RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441703-B2 | Carboxamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12441703-B2 | Carboxamides as modulators of sodium channels | TRPV1, SCN2A, SCN10A | SCN10A 3/4885GRM4 453/4885RAF1 2362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.